Posts

FDA files show lingering concerns and split views over Replimune’s melanoma drug

on

Merck–Moderna Cancer-Vaccine Trial Win Sends Stocks Higher

on

Merck–Moderna Personalized Cancer Vaccine Shows Positive Phase 3 Results

on

FDA Staff Signal Replimune RP1 Melanoma Trial Failure, Slashing Stock

on

NIH-Funded scSurvival AI Model Predicts Cancer Survival from Single-Cell Tumor Data

on

Replimune Lays Off 60% of Workforce After Second FDA Rejection of RP1 Melanoma Drug

on

FDA Rejects Replimune's RP1 Melanoma Treatment for Second Time, Citing Unresolved Trial Issues

on

Moderna and Merck Report Sustained 49% Risk Reduction in Recurrence or Death with mRNA-Keytruda Combo at Five Years in Melanoma Trial

on

TScan Cuts Workforce by 30% While Iovance Advances Amtagvi Program Amid Layoffs

on

Replimune Resubmits Melanoma Drug for FDA Approval After Initial Rejection

on

Moderna Unveils Promising mRNA-4359 Cancer Antigen Therapy Data in Melanoma Ahead of ESMO 2025

on

IO Biotech Sheds 50% of Staff After FDA Blocks Cancer Vaccine Approval Path

on

IO Biotech’s cancer vaccine Cylembio narrowly misses Phase III primary endpoint in advanced melanoma, but company eyes FDA filing in 2025

on

Scientists Protest FDA's Rejection of Replimune’s Tumor Destroying Therapy

on

Scancell's Cancer Vaccine Supercharges Melanoma Immunotherapy in Recent Trials

on

Replimune's Shares Plunge After FDA Rejects Melanoma Drug Application

on

Bristol Myers Squibb's Opdualag Fails Phase 3 Trial in Adjuvant Melanoma Treatment

on